Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2013245463B2 - Immunoglobulin Chimeric Monomer-Dimer Hybrids - Google Patents
[go: Go Back, main page]

AU2013245463B2 - Immunoglobulin Chimeric Monomer-Dimer Hybrids - Google Patents

Immunoglobulin Chimeric Monomer-Dimer Hybrids

Info

Publication number
AU2013245463B2
AU2013245463B2 AU2013245463A AU2013245463A AU2013245463B2 AU 2013245463 B2 AU2013245463 B2 AU 2013245463B2 AU 2013245463 A AU2013245463 A AU 2013245463A AU 2013245463 A AU2013245463 A AU 2013245463A AU 2013245463 B2 AU2013245463 B2 AU 2013245463B2
Authority
AU
Australia
Prior art keywords
chimeric monomer
dimer hybrids
immunoglobulin chimeric
polypeptide chain
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2013245463A
Other versions
AU2013245463A1 (en
Inventor
Alan J. Bitonti
Susan C. Low
Adam R. Mezo
Robert T. Peters
Daniel S. Rivera
James M. Stattel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioverativ Therapeutics Inc
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013204787A external-priority patent/AU2013204787B2/en
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Priority to AU2013245463A priority Critical patent/AU2013245463B2/en
Publication of AU2013245463A1 publication Critical patent/AU2013245463A1/en
Assigned to BIOGEN IDEC HEMOPHILIA INC. reassignment BIOGEN IDEC HEMOPHILIA INC. Amend patent request/document other than specification (104) Assignors: SYNTONIX PHARMACEUTICALS, INC.
Assigned to BIOGEN HEMOPHILIA INC. reassignment BIOGEN HEMOPHILIA INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: BIOGEN IDEC HEMOPHILIA INC.
Publication of AU2013245463B2 publication Critical patent/AU2013245463B2/en
Application granted granted Critical
Priority to AU2016244273A priority patent/AU2016244273B2/en
Assigned to BIOVERATIV THERAPEUTICS INC. reassignment BIOVERATIV THERAPEUTICS INC. Request to Amend Deed and Register Assignors: BIOGEN HEMOPHILIA INC.
Priority to AU2019200306A priority patent/AU2019200306B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
AU2013245463A 2003-05-06 2013-10-15 Immunoglobulin Chimeric Monomer-Dimer Hybrids Expired AU2013245463B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2013245463A AU2013245463B2 (en) 2003-05-06 2013-10-15 Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2016244273A AU2016244273B2 (en) 2003-05-06 2016-10-13 Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2019200306A AU2019200306B2 (en) 2003-05-06 2019-01-16 Immunoglobulin chimeric monomer-dimer hybrids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60/469,600 2003-05-06
US60/487,964 2003-07-17
US60/539,207 2004-01-26
AU2013204787A AU2013204787B2 (en) 2003-05-06 2013-04-12 Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2013245463A AU2013245463B2 (en) 2003-05-06 2013-10-15 Immunoglobulin Chimeric Monomer-Dimer Hybrids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2013204787A Division AU2013204787B2 (en) 2003-05-06 2013-04-12 Immunoglobulin Chimeric Monomer-Dimer Hybrids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016244273A Division AU2016244273B2 (en) 2003-05-06 2016-10-13 Immunoglobulin Chimeric Monomer-Dimer Hybrids

Publications (2)

Publication Number Publication Date
AU2013245463A1 AU2013245463A1 (en) 2013-10-31
AU2013245463B2 true AU2013245463B2 (en) 2016-07-14

Family

ID=49485875

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013245463A Expired AU2013245463B2 (en) 2003-05-06 2013-10-15 Immunoglobulin Chimeric Monomer-Dimer Hybrids

Country Status (1)

Country Link
AU (1) AU2013245463B2 (en)

Also Published As

Publication number Publication date
AU2013245463A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
HUS1600011I1 (en) Immunoglobulin chimeric monomer-dimer hybrids
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
EP1553975B8 (en) Optimized fc variants and methods for their generation
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
IL157446A0 (en) Increased recovery of active proteins
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2003011878A3 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
AU2002345804A1 (en) Antimicrobially active peptide
AU2013245463B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
WO2002074916A9 (en) Reg-like protein immunoglobulin derived proteins, compositions, methods and uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BIOVERATIV THERAPEUTICS INC.

Free format text: FORMER NAME(S): BIOGEN HEMOPHILIA INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired